Pathstone Holdings LLC Sells 3,516 Shares of Danaher Co. (NYSE:DHR)

Pathstone Holdings LLC decreased its position in Danaher Co. (NYSE:DHR - Free Report) by 3.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 108,928 shares of the conglomerate's stock after selling 3,516 shares during the quarter. Pathstone Holdings LLC's holdings in Danaher were worth $25,008,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Heck Capital Advisors LLC acquired a new position in shares of Danaher in the fourth quarter valued at approximately $27,000. Decker Retirement Planning Inc. acquired a new position in shares of Danaher in the fourth quarter valued at approximately $31,000. Golden State Wealth Management LLC acquired a new position in shares of Danaher in the fourth quarter valued at approximately $31,000. Hurley Capital LLC acquired a new position in shares of Danaher in the fourth quarter valued at approximately $34,000. Finally, Pineridge Advisors LLC grew its position in shares of Danaher by 63.3% in the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 57 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Activity

In related news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president now directly owns 15,179 shares of the company's stock, valued at $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares in the company, valued at $611,036,665.92. This trade represents a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is owned by corporate insiders.

Danaher Price Performance

Shares of DHR stock traded up $5.08 during trading hours on Friday, reaching $196.03. The company's stock had a trading volume of 3,868,501 shares, compared to its average volume of 3,454,106. The firm's 50 day simple moving average is $196.87 and its 200-day simple moving average is $217.47. The company has a market capitalization of $140.29 billion, a price-to-earnings ratio of 37.13, a PEG ratio of 2.66 and a beta of 0.80. Danaher Co. has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Sell-side analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.65%. Danaher's payout ratio is 24.85%.

Wall Street Analyst Weigh In

DHR has been the topic of several research reports. StockNews.com raised Danaher from a "hold" rating to a "buy" rating in a research report on Monday, May 12th. The Goldman Sachs Group reduced their price target on Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. JPMorgan Chase & Co. reduced their price target on Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 22nd. Wells Fargo & Company reduced their price target on Danaher from $280.00 to $240.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. Finally, Raymond James reissued a "market perform" rating on shares of Danaher in a research report on Monday, February 3rd. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and a consensus price target of $264.40.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.